Cargando…
Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval Zebrafish
Meclozine has been developed as an inhibitor of fibroblast growth factor receptor 3 (FGFR3) to treat achondroplasia (ACH). Extracellular signal regulated kinase (ERK) phosphorylation was attenuated by meclozine in FGF2-treated chondrocyte cell line, but the site of its action has not been elucidated...
Autores principales: | Takemoto, Genta, Matsushita, Masaki, Okamoto, Takaaki, Ito, Toshinari, Matsuura, Yuki, Takashima, Chieko, Chen-Yoshikawa, Toyofumi Fengshi, Ebi, Hiromichi, Imagama, Shiro, Kitoh, Hiroshi, Ohno, Kinji, Hosono, Yasuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804316/ https://www.ncbi.nlm.nih.gov/pubmed/35118060 http://dx.doi.org/10.3389/fcell.2021.694018 |
Ejemplares similares
-
Meclozine ameliorates bone mineralization and growth plate structure in a mouse model of X‑linked hypophosphatemia
por: Kamiya, Yasunari, et al.
Publicado: (2022) -
Meclozine Facilitates Proliferation and Differentiation of Chondrocytes by Attenuating Abnormally Activated FGFR3 Signaling in Achondroplasia
por: Matsushita, Masaki, et al.
Publicado: (2013) -
Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia
por: Matsushita, Masaki, et al.
Publicado: (2017) -
Evolution of hyperossification expands skull diversity in frogs
por: Paluh, Daniel J., et al.
Publicado: (2020) -
Efficacy of soluble lansoprazole-impregnated beta-tricalcium phosphate for bone regeneration
por: Mishima, Kenichi, et al.
Publicado: (2022)